TREATMENT OF RETINAL DEGENERATION USING PROGENITOR CELLS

• US 20170157179A1
• Filed: 12/01/2016
• Published: 06/08/2017
• Est. Priority Date: 12/04/2015
• Status: Abandoned Application

• Current Assignee: Janssen Biotech, Inc. (Johnson & Johnson)
• Original Assignee: Janssen Biotech, Inc. (Johnson & Johnson)
• Inventors: Harris, Ian R., Cao, Jing, Dejneka, Nadine
• Application Number:
  US15/366,599
• Publication Number:
  US 20170157179A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61K 35/51 Umbilical cord; Umbilical cord blood; Umbilical stem cells
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61P 27/02 Ophthalmic agents

Abstract

Methods and compositions for treating and reducing retinal degeneration using progenitor cells and conditioned media from progenitor cells, such as postpartum-derived cells are disclosed. Genetic factors and receptors expressed by the progenitor cells that aid in protection of retinal cells and inhibition of apoptosis of retinal cells such as photoreceptor cells are also disclosed.

Claims

1. A method for reducing the loss of photoreceptor cells in retinal degeneration, the method comprising administering to the eye of a subject a composition comprising a population of postpartum-derived cells in an amount effective to reduce the loss of photoreceptor cells, wherein the postpartum-derived cells are isolated from human umbilical cord tissue substantially free of blood, and wherein the population of postpartum-derived cells modulates phagocytic receptors α

vβ

5 integrin and CD36.

2. The method of claim 1, wherein the postpartum-derived cells secrete bridge molecules selected from MFG-E8, Gas6, thrombospondin (TSP)-1 and TSP-2, and wherein the bridge molecules bind to phagocytic receptors α

vβ

5 integrin and CD36.

3. The method of claim 1, wherein the cell population isolated from human umbilical cord tissue substantially free of blood is capable of expansion in culture, has the potential to differentiate into cells of at least a neural phenotype, maintains a normal karyotype upon passaging, and has the following characteristics:

a) potential for 40 population doublings in culture;

b) production of CD10, CD13, CD44, CD73, and CD90;

c) lack of production of CD31, CD34, CD45, CD117, and CD141, and

d) increased expression of genes encoding interleukin 8 and reticulon 1 relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell.

4. The method of claim 1, wherein the composition is a pharmaceutical composition.

5. The method of claim 1, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier.

6. The method of claim 1, wherein the retinal degeneration is age-related macular degeneration.

7. The method of claim 6, wherein the age-related macular degeneration is dry age-related macular degeneration.

8. The method of claim 2, wherein the cell population is positive for HLA-A, B, C, and negative for HLA-DR, DP, DQ.

9. The method of claim 1, wherein administration to the eye is selected from administration to the interior of an eye or administration behind the eye.

10. A method of treating ocular degeneration in a subject comprising administering to an eye of the subject a composition comprising a population of postpartum-derived cells in an amount effective to treat the ocular degeneration, wherein the postpartum-derived cells are isolated from human umbilical cord tissue substantially free of blood, and wherein the population of postpartum-derived cells modulates phagocytic receptors α

vβ

5 integrin and CD36.

11. The method of claim 10, wherein the postpartum-derived cells secrete bridge molecules selected from MFG-E8, Gas6, thrombospondin (TSP)-1 and TSP-2, and wherein the bridge molecules bind to phagocytic receptors α

vβ

5 integrin and CD36.

12. The method of claim 10, wherein the cell population isolated from human umbilical cord tissue substantially free of blood is capable of expansion in culture, has the potential to differentiate into cells of at least a neural phenotype, maintains a normal karyotype upon passaging, and has the following characteristics:

a) potential for 40 population doublings in culture;

b) production of CD10, CD13, CD44, CD73, and CD90;

c) lack of production of CD31, CD34, CD45, CD117, and CD141, and

d) increased expression of genes encoding interleukin 8 and reticulon 1 relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell.

13. The method of claim 10, wherein the composition is a pharmaceutical composition.

14. The method of claim 10, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier.

15. The method of claim 10, wherein the retinal degeneration is age-related macular degeneration.

16. The method of claim 15, wherein the age-related macular degeneration is dry age-related macular degeneration.

17. The method of claim 11, wherein the cell population is positive for HLA-A, B, C, and negative for HLA-DR, DP, DQ.

18. The method of claim 10, wherein administration to the eye is selected from administration to the interior of an eye or administration behind the eye.

19. A method of clearing apoptotic retinal cells by phagocytes in the eye comprising administering a population of postpartum-derived cells to the eye of a subject, wherein the postpartum-derived cells are isolated from human umbilical cord tissue substantially free of blood, and wherein the population of postpartum-derived cells modulates phagocytic receptors α

vβ

5 integrin and CD36.

20. The method of claim 19, wherein the postpartum-derived cells secrete bridge molecules selected from MFG-E8, Gas6, thrombospondin (TSP)-1 and TSP-2, and the bridge molecules modulate the phagocytic receptors α

vβ

5 integrin and CD36.